6 October 2022
EFPIA Japan

EFPIA Japan holds EFPIA Day 2022 press conference- Contributing its knowledge and experience in Europeto realize its vision for the future of people and society in Japan TOKYO – 6 October 2022 – European Federation of Pharmaceutical Industries and Associations
Japan (EFPIA Japan) held an EFPIA Day 2022 press conference on 6 October, 2022, andexplained its ambition and strategies to continuously strengthen the pharmaceutical industry inJapan and increase the market attractiveness in line with its five basic strategies to drive
innovation and enhance its contribution to the people and government in Japan.
To bring pharmaceutical innovations quickly to the country and improve the health and quality oflife of the people in Japan, EFPIA Japan works with the government and stakeholders, makes
policy recommendations, and raises awareness on issues in the pharmaceutical industry. Incelebrating its 20th anniversary of the establishment of EFPIA Japan this year, it was reorganized
as a general incorporated association to further strengthen its policy advocacy and initiatives as
an industry group, and to ensure the sustainability of its activities over the long term. In the faceof the evolving country and international environment as well as the public health and geopoliticalcrises, the question is how EFPIA Japan as a pharmaceutical industry organization can contributeto solving emerging societal issues going forward. To this end, EFPIA Japan has developed fivebasic strategies to identify its vision of the future and actions to bring the vision into life.
EFPIA Japan has identified the following four states as its vision of the future: "Increased publichealth awareness leads to promotion of prevention, early detection, and early treatment ofdiseases, thereby extending healthy life expectancy;" "All people live in harmony, allowing eachindividual to be oneself despite illness or disability;" "Safe and effective pharmaceuticals areavailable in Japan without delay from other countries;" and "All people have equal access to thelatest medicine and lead healthy lives”. To realize them, EFPIA Japan aims to continuouslystrengthen the pharmaceutical industry in Japan and increase the market attractiveness based on
its five basic strategies. Further, to execute the strategies, EFPIA Japan will build a resilientorganization, strengthen collaboration between Japan and Europe, and make distinctive
contributions to society.

EFPIA JapanTokyo Opera City Tower, 3-20-2, Nishi Shinjuku, Shinjuku-ku, Tokyo, Japan1) Support the enhancement of health literacy
EFPIA Japan works with the government and the healthcare community to support the healthliteracy in patients, as healthcare recipients’ literacy and interest in health is an important factor in
improving the quality of healthcare.
2) Drive pharmaceutical innovation while sustaining universal healthcare
While maintaining the advantages of the current healthcare system in Japan that allows promptprice listing and reimbursement of new pharmaceuticals after regulatory approval, it is necessary
to build a sustainable system to balance the financial sustainability and the market attractiveness.
To this end, EFPIA Japan carries on in-depth debates with stakeholders on incentivizing new drug
launches in Japan ahead of the world and on allowing more flexibility in the new drug evaluation
processes.
3) Be engaged in the development of cost-effectiveness assessment processes
The use of health technology assessment (HTA) based on cost-effectiveness as a priceadjustment tool after listing involves both scientific and operational challenges. EFPIA Japan
believes that an appraisal with the participation of physicians and patients is necessary toappropriately evaluate the value of pharmaceuticals and address the shortfall of the current costeffectiveness assessment system. EFPIA Japan is committed to the development and realizationof appropriate cost-effectiveness assessment processes by reflecting solutions to the challenges
faced by Europe ahead of Japan and incorporating the diverse value of pharmaceuticals.
4) Promote the improvement of R&D and regulatory environment
To enable Japan to remain internationally attractive and competitive in the development ofinnovative pharmaceuticals and vaccines, and ultimately ensure that the people in Japan
continue to benefit from the latest innovations, EFPIA Japan regularly investigates the clinical trial
environment, encourages networking of core clinical research hospitals, promotes a risk-based
approach, and facilitates decentralized clinical trials.
5) Leverage digital technologies and develop digital talent
To effectively allocate limited healthcare resources, it is necessary to correct inefficiencies inhealthcare. Digital technologies can play a significant role in this regard. To utilize digitaltechnologies to increase the healthcare efficiency, allocate healthcare resources appropriately,and improve health outcomes, the government needs to take the lead in forming a framework forEFPIA JapanTokyo Opera City Tower, 3-20-2, Nishi Shinjuku, Shinjuku-ku, Tokyo, Japandigital technology use, including the development of a data infrastructure and its incorporation
into community healthcare. Further, talents with both macro perspectives on the healthcare
system and patient-oriented micro perspectives, who can look ahead to the utilization of evolving
technology seeds may serve as a bridge between the pharmaceutical industry and society. To thisend, EFPIA Japan develops such talents in the industry building on the experiences in Europe.
In the press conference, Hubertus von Baumbach, President of EFPIA, and Takahiko Iwaya,
Chair of EFPIA Japan, explained the current state of the pharmaceutical market in Japan as wellas the significance of the pharmaceutical industry and challenges for the future. In addition, a talksession entitled "Patient Involvement and Challenges for Healthcare Advancement from Patient
Perspectives” was held joined by Mr. Yoshiyuki Majima (President of Pancreatic Cancer Action
Network and President of Rare Cancer Japan) as a guest speaker. Further, an award ceremony
was held for the 5th PASE AWARD, which is part of the Patient Advocacy Support by EFPIA
Japan (PASE) program to support patient organizations.

About EFPIA Japan (http://efpia.jp/)
Established in April 2002, EFPIA Japan represents 23 R&D-based European pharmaceuticalcompanies operating in Japan. In 2021, combined sales from the member companies accounted
for roughly 26% of the pharmaceutical market in Japan. The mission of EFPIA Japan is to“Contribute to healthcare and patients in Japan through the early introduction of innovative
medicines and vaccines”. EFPIA Japan aims to strengthen dialogue with decision-makers in orderto improve Japanese healthcare for all.

About EFPIA (European Federation of Pharmaceutical Industries and Associations)(https://www.efpia.eu/)
The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents thebiopharmaceutical industry operating in Europe. Through its direct membership of 37 national
associations, 38 leading pharmaceutical companies and a growing number of small and mediumsized enterprises (SMEs), EFPIA’s mission is to create a collaborative environment that enables
our members to innovate, discover, develop and deliver new therapies and vaccines for people
across Europe, as well as contribute to the European economy.

EFPIA JapanTokyo Opera City Tower, 3-20-2, Nishi Shinjuku, Shinjuku-ku, Tokyo, Japan

Contact:
Yuko Kidoguchi
EFPIA Japan Communications Committee
1-6-5 Marunouchi Chiyoda-ku, Tokyo 100-8268
Bayer Holding Ltd.
Tel: 03-6266-7757
Email: yuko.kidoguchi@bayer.com

EFPIA JapanTokyo Opera City Tower, 3-20-2, Nishi Shinjuku, Shinjuku-ku, Tokyo, Japan